| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 2976627 | Journal des Maladies Vasculaires | 2007 | 4 Pages | 
Abstract
												Calf vein thrombosis corresponds to infrapopliteal deep vein thrombosis which accounts for roughly 50% of all cases of deep vein thrombosis and shares the same risk factors as proximal deep vein thrombosis. The complication rate and proper management remain debated. Recent studies suggest that the risk of proximal extension of calf vein thrombosis is 1 to 5% and that the risk of postthrombotic syndrome is 3%. In France, calf vein thrombosis is usually treated with compression stockings associated with a six week to three month regimen of anticoagulation therapy in patients presenting a transient triggering factor or longer otherwise. However, the benefit of such treatment, in terms of the hemorragic risk incurred, remains uncertain. The randomized double blind trial CACTUS (compression stocking + placebo versus compression stocking + heparin, for six weeks) that will start in September 2007, should provide answers the following question: should calf vein thrombosis be treated with anticoagulants?
											Keywords
												
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Cardiology and Cardiovascular Medicine
												
											Authors
												J.-P. Galanaud, A. Khau Van Kien, C. Boubakri, G. Böge, J.-P. Laroche, I. Quéré, 
											